Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
440
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro

Narjis Fatimaa Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia;b School of Life and Environmental Sciences, University of Sydney, Camperdown, AustraliaView further author information
,
Yandong Shena Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia;b School of Life and Environmental Sciences, University of Sydney, Camperdown, AustraliaView further author information
,
Kyle Crassinia Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, AustraliaView further author information
,
Olivia Burlingc Flinders Health and Medical Research Institute, Department of Genetics and Molecular Medicine, College of Medicine and Public Health, Flinders University, Camperdown, AustraliaView further author information
,
Lauren Thurgoodc Flinders Health and Medical Research Institute, Department of Genetics and Molecular Medicine, College of Medicine and Public Health, Flinders University, Camperdown, AustraliaView further author information
,
Edwin J. Iwanowiczd Madera Therapeutics, LLC, Cary, North Carolina, USAView further author information
,
Henk Langd Madera Therapeutics, LLC, Cary, North Carolina, USAView further author information
,
Donald S. Karanewskyd Madera Therapeutics, LLC, Cary, North Carolina, USAView further author information
,
Richard I. Christophersonb School of Life and Environmental Sciences, University of Sydney, Camperdown, AustraliaView further author information
,
Stephen P. Mulligana Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia;b School of Life and Environmental Sciences, University of Sydney, Camperdown, AustraliaView further author information
&
O. Giles Besta Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia;b School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia;c Flinders Health and Medical Research Institute, Department of Genetics and Molecular Medicine, College of Medicine and Public Health, Flinders University, Camperdown, AustraliaCorrespondence[email protected]
View further author information
 show all
Pages 585-597 | Received 24 Oct 2022, Accepted 11 Dec 2023, Published online: 16 Jan 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.